Cutoff Value of Qualitative HBsAg for Confirmatory HBsAg Using the Chemiluminescence Microparticle Immunoassay Method.

CMIA HBsAg Qualitative II HBsAg Qualitative II Confirmatory S/CO value false positive hepatitis B

Journal

Laboratory medicine
ISSN: 1943-7730
Titre abrégé: Lab Med
Pays: England
ID NLM: 0250641

Informations de publication

Date de publication:
01 Sep 2022
Historique:
pubmed: 9 4 2022
medline: 8 9 2022
entrez: 8 4 2022
Statut: ppublish

Résumé

Confirmatory hepatitis B surface antigen (HBsAg) is an assay used to distinguish weakly reactive from false-positive HBsAg results. To determine the signal to cutoff (S/CO) value of chemiluminescence microparticle immunoassay (CMIA) HBsAg assay that should trigger follow-up confirmatory HBsAg testing. All specimens with an initial S/CO value of 0.90-100.00 were subjected to repeat HBsAg testing after high-speed centrifugation. The specimens with an initial S/CO value in that range remained in the same range and were then followed up with confirmatory HBsAg testing. In total, 132 specimens had an S/CO value between 0.90 and 100.00 after high-speed centrifugation, followed by confirmatory HBsAg retesting. The S/CO value of HBsAg specimens for which the results required verification with confirmatory HBsAg was 0.98 (100% sensitivity, 3.3% specificity) through 9.32 (47.1% sensitivity, 100% specificity). The HBsAg S/CO values (as determined by the chemiluminescent microparticle immunoassay [CMIA] method) that should trigger confirmatory HBsAg testing are 0.98-9.32.

Sections du résumé

BACKGROUND BACKGROUND
Confirmatory hepatitis B surface antigen (HBsAg) is an assay used to distinguish weakly reactive from false-positive HBsAg results.
OBJECTIVE OBJECTIVE
To determine the signal to cutoff (S/CO) value of chemiluminescence microparticle immunoassay (CMIA) HBsAg assay that should trigger follow-up confirmatory HBsAg testing.
METHODS METHODS
All specimens with an initial S/CO value of 0.90-100.00 were subjected to repeat HBsAg testing after high-speed centrifugation. The specimens with an initial S/CO value in that range remained in the same range and were then followed up with confirmatory HBsAg testing.
RESULT RESULTS
In total, 132 specimens had an S/CO value between 0.90 and 100.00 after high-speed centrifugation, followed by confirmatory HBsAg retesting. The S/CO value of HBsAg specimens for which the results required verification with confirmatory HBsAg was 0.98 (100% sensitivity, 3.3% specificity) through 9.32 (47.1% sensitivity, 100% specificity).
CONCLUSION CONCLUSIONS
The HBsAg S/CO values (as determined by the chemiluminescent microparticle immunoassay [CMIA] method) that should trigger confirmatory HBsAg testing are 0.98-9.32.

Identifiants

pubmed: 35394549
pii: 6565498
doi: 10.1093/labmed/lmac021
doi:

Substances chimiques

Hepatitis B Surface Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

475-478

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Merci Monica Pasaribu (MM)

Department of Clinical Pathology, Faculty of Medicine University of Indonesia/ National General Hospital Dr Cipto Mangunkusumo, Jakarta, Indonesia.

Jessica Purwanti Wonohutomo (JP)

Department of Clinical Pathology, Faculty of Medicine University of Indonesia/ National General Hospital Dr Cipto Mangunkusumo, Jakarta, Indonesia.

Suzanna Immanuel (S)

Department of Clinical Pathology, Faculty of Medicine University of Indonesia/ National General Hospital Dr Cipto Mangunkusumo, Jakarta, Indonesia.

July Kumalawati (J)

Department of Clinical Pathology, Faculty of Medicine University of Indonesia/ National General Hospital Dr Cipto Mangunkusumo, Jakarta, Indonesia.

Nuri Dyah Indrasari (ND)

Department of Clinical Pathology, Faculty of Medicine University of Indonesia/ National General Hospital Dr Cipto Mangunkusumo, Jakarta, Indonesia.

Yusra Yusra (Y)

Department of Clinical Pathology, Faculty of Medicine University of Indonesia/ National General Hospital Dr Cipto Mangunkusumo, Jakarta, Indonesia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH